These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Overview of EBV-Associated T/NK-Cell Lymphoproliferative Diseases. Kimura H; Fujiwara S Front Pediatr; 2018; 6():417. PubMed ID: 30662890 [TBL] [Abstract][Full Text] [Related]
8. Clinicopathological categorization of Epstein-Barr virus-positive T/NK-cell lymphoproliferative disease: an analysis of 42 cases with an emphasis on prognostic implications. Paik JH; Choe JY; Kim H; Lee JO; Kang HJ; Shin HY; Lee DS; Heo DS; Kim CW; Cho KH; Kim TM; Jeon YK Leuk Lymphoma; 2017 Jan; 58(1):53-63. PubMed ID: 27157296 [TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr Virus-associated Lymphoproliferative Disorders in the Skin. Goodlad JR Surg Pathol Clin; 2017 Jun; 10(2):429-453. PubMed ID: 28477890 [TBL] [Abstract][Full Text] [Related]
10. Hydroa Vacciniforme and Hydroa Vacciniforme-Like Lymphoproliferative Disorder: A Spectrum of Disease Phenotypes Associated with Ultraviolet Irradiation and Chronic Epstein-Barr Virus Infection. Chen CC; Chang KC; Medeiros LJ; Lee JY Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33297336 [TBL] [Abstract][Full Text] [Related]
11. Atypical hydroa vacciniforme-like epstein-barr virus associated T/NK-cell lymphoproliferative disorder. Lee HY; Baek JO; Lee JR; Park SH; Jeon IS; Roh JY Am J Dermatopathol; 2012 Dec; 34(8):e119-24. PubMed ID: 23169419 [TBL] [Abstract][Full Text] [Related]
12. EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases. Kimura H; Ito Y; Kawabe S; Gotoh K; Takahashi Y; Kojima S; Naoe T; Esaki S; Kikuta A; Sawada A; Kawa K; Ohshima K; Nakamura S Blood; 2012 Jan; 119(3):673-86. PubMed ID: 22096243 [TBL] [Abstract][Full Text] [Related]
13. Spectrum of Epstein-Barr virus-associated T-cell lymphoproliferative disorder in adolescents and young adults in Taiwan. Wang RC; Chang ST; Hsieh YC; Huang WT; Hsu JD; Tseng CE; Wang MC; Hwang WS; Wang J; Chuang SS Int J Clin Exp Pathol; 2014; 7(5):2430-7. PubMed ID: 24966953 [TBL] [Abstract][Full Text] [Related]
14. Clinicopathological categorization of hydroa vacciniforme-like lymphoproliferative disorder: an analysis of prognostic implications and treatment based on 19 cases. Guo N; Chen Y; Wang Y; Huang Y; Feng Y; Li M; Rao H Diagn Pathol; 2019 Jul; 14(1):82. PubMed ID: 31315684 [TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008. Cohen JI; Kimura H; Nakamura S; Ko YH; Jaffe ES Ann Oncol; 2009 Sep; 20(9):1472-1482. PubMed ID: 19515747 [TBL] [Abstract][Full Text] [Related]
17. An update on Epstein-Barr virus-and human T-lymphotropic virus type-1-induced cutaneous manifestations. CME Part II. Gru AA; Plaza JA; Sanches JA; Miyashiro D; Sangueza OP; Puccio FB; Toussaint S; Sangueza JM J Am Acad Dermatol; 2023 May; 88(5):983-998. PubMed ID: 36049582 [TBL] [Abstract][Full Text] [Related]
19. Central nervous system vasculitis from Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disorder in children: A case report. Lee MS; Hwang SK; Kim YE; Suh JK; Kim H; Lee SM; Jeong JY; Kwon S; Lee YJ Brain Dev; 2019 Oct; 41(9):820-825. PubMed ID: 31208818 [TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr virus: dermatologic associations and implications: part II. Associated lymphoproliferative disorders and solid tumors. Eminger LA; Hall LD; Hesterman KS; Heymann WR J Am Acad Dermatol; 2015 Jan; 72(1):21-34; quiz 35-6. PubMed ID: 25497918 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]